Life Science News

Naturally Splendid Enterprises Ltd. ("Naturally Splendid") (TSXV:NSP)(OTC PINK:NSPDF)(Frankfurt:50N) is pleased to announce the Company has executed a National Food Service Broker Agreement with Vancouver based Tri-Elite Marketing Ltd. (Tri-Elite), to market the Company's plant-based entrees, PlanteinTM, across Canada

Tri-Elite will focus on securing food service listings across Canada for the Company's extensive line of plant-based, meat alternative entrees. Tri-Elite will be participating with Naturally Splendid at the Canadian Health Food Association (CHFA) trade show this weekend, April 23rd and 24th, promoting the PlanteinTM line to its many existing clients and looking to make connections with new opportunities. Industry experts consider the CHFA trade shows the number one source of presenting new products to retailers doing business in Canada.

Tri-Elite Marketing Ltd. was founded in 2000 servicing western Canada initially. In 2003, current President Aggie Christopher, joined Tri-Elite as a partner bringing her extensive experience, relationships and distribution background to the company. In 2009 Aggie assumed full ownership of the company and its direction, expanding Company operations across Canada.

In 2018 Tri-Elite stepped into the national arena hiring territory managers for eastern Canada solidifying strong representation coast to coast. The Company has over twenty (20) full-time sales representatives across Canada dedicated to servicing Tri-Elite clients and expanding their distribution. The company has been built on hard work, loyalty, trust and finding the best sales candidates in each marketplace. Tri-Elite has been truly fortunate to have hired some of the best talents in the Food Service Industry and that has been the key to the success of the brands they represent and in turn, Tri-Elite's success.

Tri-Elite President Aggie Christopher states, "Tri-Elite Marketing is a partner for the future, with lofty targets and goals to provide premium service for our business partners supporting them to build their business and ultimately succeed. Consumers are demanding plant-based products more now than ever before and we believe this category will continue to grow. We deploy a very strategic game plan with goals to grow our vendor partner's business, while in turn continuing to build Tri-Elite Marketing to be the strongest and most focused brokerage company in Canada. We look forward to implementing the systems and processes we've developed over our decades of doing business that have proven to be successful and look forward to working with the Naturally Splendid team to make the PlanteinTM brand a sensation in Canada."

PlanteinTM is the brand name for Naturally Splendid's line of plant-based entrees (www.plantein.ca). Naturally Splendid has an exclusive manufacturing and distribution agreement for an extensive range of plant-based entrees with Flexitarian Foods Pty. Ltd., a division of Australia's largest plant-based manufacturer. The current roster of entrees that Naturally Splendid has initially launched under the PlanteinTM trademark, include a plant-based; Burger; Crunchy Burger; Crumbed Tenders; Sweet Chili Tenders; Nuggets; Schnitzel (cutlet); Garlic Kiev; and a Phishy Filet.

Naturally Splendid CEO Craig Goodwin comments, "We are very pleased that our initial PlanteinTM launch and subsequent rollout strategy is being supported by an organization as successful as Tri-Elite Marketing. Their understanding and achievements regarding product launches and national distribution will significantly benefit our sales and distribution strategies. We look forward to working with the Tri-Elite team with our most exciting product launch to date."

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a plant-based food manufacturing and technology company that produces and distributes nutritious and delicious plant-based commodity products.

Founded in 2010, the Company operates a Safe Quality Food Level 2 certified food manufacturing facility located just outside Vancouver, BC in Canada, focusing on producing an extensive range of plant-based entrees.

Naturally Splendid has an exclusive 10-year manufacturing and distribution agreement for Canada with a division of Australia's largest plant-based food manufacturer, Flexitarian Foods Pty. Ltd.

In addition to producing the Company's own branded products, Naturally Splendid provides contract manufacturing services and private labeling for a variety of nutritional plant-based food products destined for multiple distribution channels.

The Company has established healthy, functional foods under brands such as Natera Sport™, Natera Hemp Foods™, CHII™, Elevate Me™ and Woods Wild Bar™. The Company launched Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

Naturally Splendid maintains a relationship Plasm Pharmaceutical, a company that has been approved for conducting a phase 2 clinical trial approved by Health Canada for the treatment of COVID-19.

NSE has also developed proprietary technologies for the extraction of healthy omega 3 and 6 oils, as well as a protein concentrate from hemp.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-570-0905 x 101.

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 570-0902
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/698464/Naturally-Splendid-Announces-National-Food-Service-Broker-Agreement-With-Tri-Elite-Marketing

News Provided by ACCESSWIRE via QuoteMedia

NSP:CA
Naturally Splendid Enterprises

Naturally Splendid Enterprises


Keep reading...Show less
Plantein Presenting at Canada's Largest Plant-Based Event

Plantein Presenting at Canada's Largest Plant-Based Event

Naturally Splendid Enterprises Ltd. ("Naturally Splendid") (TSXV:NSP)(OTC PINK:NSPDF)(Frankfurt:50N) is pleased to announce we will be presenting the PlanteinTM line of plant-based entrees at the Planted Expo Vancouver on June 4 and June 5, 2022, at the Vancouver Convention Center

Planted Expo is Canada's largest plant-based event of the year, focused on consumers looking to add more plant-based choices to their daily diets. Planted Expo expects more than 15,000 plant-based enthusiasts to attend this two-day event.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Provides Default Status Report

Naturally Splendid Provides Default Status Report

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRANKFURT:50N) (TSXV:NSP) (OTC PINK:NSPDF) today is providing a status update in accordance with its obligations under the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), which require the Company to provide bi-weekly updates until such time as the Company is current with its filing obligations under Canadian securities laws. As previously announced, the Company is subject to a management cease trade order ("MCTO") issued by the British Columbia Securities Commission. The MCTO prohibits the directors and executive officers of the Company from trading in or acquiring securities of the Company until two full business days after the Company files its audited financial statements for the year ended December 31, 2021 and the related management's discussion and analysis and certifications. The MCTO does not affect the ability of investors who are not insiders to trade in the securities of the Company

The Company advises that aside from the British Columbia Securities Commission granting the MCTO: (i) there have been no material changes to the information contained in the Company's April 14, 2022 news release; (ii) it intends to continue to comply with the alternative information guidelines of NP 12-203; and (iii) except as previously disclosed, there are no subsequent specified defaults (actual or anticipated) within the meaning of NP 12-203.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
George Ragogna Appointed CFO

George Ragogna Appointed CFO

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce that Mr. George Ragogna has been appointed Chief Financial Officer (CFO), replacing current Chief Financial Officer (CFO), Mr. Bryan Carson

Mr. Ragogna has over 30 years of experience in the Canadian financial services industry with over 20 years in a progressive leadership role specializing in; strategic planning, corporate sales, workforce optimization and regulatory compliance for the Co-operators Group Limited, a leading Canadian multi-line insurance and financial services co-operative with $56.4 billion in assets under management.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that it has closed the second tranche of its previously announced non-brokered private placement financing (the "Financing") (see news release dated November 23, 2021 and December 23, 2021) by issuing 37,348,532 Units (each a "Unit") at a price of $0.03 per Unit for gross proceeds of $1,120,455.96 (the "Second Tranche"). In total, the Company has issued 109,032,378 Units for gross proceeds of $3,270,971.34 under the entire private placement financing. The Financing has been oversubscribed by $270,971.34

Each Unit in the Second Tranche consists of one common share of Naturally Splendid and one common share purchase warrant (each a "Warrant"), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.05 per share.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Closes First Tranche of $2,150,515

Naturally Splendid Closes First Tranche of $2,150,515

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRA:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that it has closed the first tranche of its previously announced non-brokered private placement financing (see news release dated November 23, 2021) by issuing 71,683,846 Units (each a "Unit") at a price of $0.03 per Unit for gross proceeds of $2,150,515 (the "First Tranche

Each Unit in the First Tranche consists of one common share of Naturally Splendid and one common share purchase warrant (each a "Warrant"), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.05 per share.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

I n the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile

Approval was also based on data from the Phase 2 PILOT study, the first and only company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL who are not considered candidates for transplant, in which Breyanzi delivered deep and durable responses

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

I n the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile

Approval was also based on data from the Phase 2 PILOT study, the first and only company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL who are not considered candidates for transplant, in which Breyanzi delivered deep and durable responses

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis

Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5% improved and 34.1% preserved) at Month 48 of the DAYBREAK open-label extension trial

Zeposia was well tolerated, with more than 80% of people staying on therapy through 48 months

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia

Analysis of ongoing DAYBREAK open-label extension trial of Zeposia showed that seroconversion occurred in 100% of those treated with mRNA vaccines and in a majority of those treated with non-mRNA vaccines

New analyses to be featured in late-breaking research session at the 8th European Academy of Neurology Congress in Vienna, Austria

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

  • Anti-Cancer activity of BriaCell's lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication.
  • Bria-IMT™, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria-IMT™ HLA types, supporting BriaCell's platform strategy of developing off-the-shelf personalized immunotherapy for multiple cancer indications.
  • The clinical data, previously reported, included rapid tumor reduction and extended survival.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the publication of novel scientific data and clinical data (previously reported) on BriaCell's lead candidate, Bria-IMT™. The abstract of the paper was published on-line in Recent Patents on Anti-Cancer Drug Discovery a publication focused on research (where patents have been registered) in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery. The publication highlights BriaCell's approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT™ against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action. The full text of the article will be made available.

"We are thrilled to see the congruence of our scientific insights and the clinical activity of our immunotherapy in advanced breast cancer patients," stated Dr. Williams, BriaCell's President & CEO. "This paper highlights our findings of rapid tumor shrinkage in multiple anatomic locations including difficult to treat sites like the brain. We are even more excited to see the potential positive effect on survival in these patients. Having these scientific and clinical findings published in such a highly regarded journal is a significant achievement for BriaCell. The results support our approach for selecting patients most likely to benefit from our immunotherapy. This undergirds our current strategy of building a pipeline of off-the-shelf personalized immunotherapies as potentially safe and effective treatments for advanced breast cancer and other cancers," Dr. Williams added.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV –

– If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×